SGLT2 Inhibitor-Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event

被引：3
|
作者：
Tukker, Martijn [1 ]
Bruwiere, Ewout [1 ]
Bos, Sven [2 ]
Caliskan, Kadir [1 ,3 ]
机构：
[1] Erasmus MC Univ Med Ctr Rotterdam, Dept Cardiol, Thoraxctr, Rotterdam, Netherlands
[2] Erasmus MC Univ Med Ctr Rotterdam, Dept Haematol, Rotterdam, Netherlands
[3] Erasmus MC Univ Med Ctr Rotterdam, Dept Cardiol, Room RG 431,Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
来源：
CIRCULATION-HEART FAILURE | 2023年 / 16卷 / 07期
关键词：
adverse drug event; dapagliflozin; erythrocytosis; heart failure; polycythemia;
D O I：
10.1161/CIRCHEARTFAILURE.123.010613
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
According to the current heart failure guidelines, SGLT2 (sodium glucose cotransporter 2) inhibitors are increasingly prescribed in patients with heart failure (HF).1 However, SGLT2-inhibitors are known to increase hemoglobin (Hb) and hematocrit (Ht) levels, but literature on SGLT2-induced erythrocytosis is limited. We provide a case of a patient with chronic HF with severe polycythemia associated with dapagliflozin usage, suggesting the potential importance of hemoglobin and hematocrit monitoring. © 2023 Lippincott Williams and Wilkins. All rights reserved.
引用
收藏
页数：3
相关论文
共 50 条
  • [31] The Potential of SGLT2 Inhibitors to Counteract Anemia in Patients with Heart Failure
    Kow, Chia Siang
    Zaihan, Abdullah Faiz
    Thiruchelvam, Kaeshaelya
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2025, 40 (03) : 723 - 724
  • [32] Adverse Effects Of Sglt2 Inhibitors In Older Patients With Congestive Heart Failure And The Influence Of Chronic Kidney Disease
    Mahmood, Riaz
    Robinson, Shane
    Kilaru, Vikas
    Amoran, Olayiwola
    Egolum, Ugochukwu
    JOURNAL OF CARDIAC FAILURE, 2025, 31 (01)
  • [33] Reduced tissue sodium content is related to improvement of vascular function in patients with chronic heart failure treated with the SGLT2 inhibitor empagliflozin
    Kolwelter, J.
    Kannenkeril, D.
    Linz, P.
    Jung, S.
    Nagel, A. M.
    Bosch, A.
    Ott, C.
    Bramlage, P.
    Uder, M.
    Achenbach, S.
    Schmieder, R. E.
    EUROPEAN HEART JOURNAL, 2021, 42 : 795 - 795
  • [34] Sotagliflozin, A Dual SGLT1 And SGLT2 Inhibitor, Reduces First And Subsequent Heart Failure-related Events In Patients Admitted For Worsening Heart Failure
    Pitt, Bertram
    Szarek, Michael
    Banks, Phillip
    Sun, Franklin
    Davies, Michael
    Bhatt, Deepak
    JOURNAL OF CARDIAC FAILURE, 2023, 29 (04) : 683 - 684
  • [35] Could SGLT2 Inhibitors Improve Exercise Intolerance in Chronic Heart Failure?
    Voorrips, Suzanne N.
    Saucedo-Orozco, Huitzilihuitl
    Sanchez-Aguilera, Pablo I.
    De Boer, Rudolf A.
    van der Meer, Peter
    Westenbrink, B. Daan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (15)
  • [36] SGLT2 inhibitor therapy in patients with advanced heart failure and reduced ejection fraction
    Nuzzi, Vincenzo
    Manca, Paolo
    Parisi, Francesca
    Madaudo, Cristina
    Sciacca, Sergio
    Cannizzo, Noemi
    Mule, Massimiliano
    Cipriani, Manlio G.
    CURRENT PROBLEMS IN CARDIOLOGY, 2024, 49 (11)
  • [37] Risk factors associated with SGLT2 inhibitor discontinuation in diabetic patients with heart failure
    Kim, Minkwan
    Heo, Seok-Jae
    Kim, Moon-Hyun
    Park, Je-Wook
    Bae, Sunga
    Roh, Ji Woong
    Lee, Oh-Hyun
    Kim, Yongcheol
    Im, Eui
    Jung, In Hyun
    Cho, Deok-Kyu
    PLOS ONE, 2024, 19 (11):
  • [38] Canagliflozin, An SGLT2 Inhibitor, Prevents Lung Remodeling in Chronic Left Ventricular Failure
    Kanuparthy, M.
    Harris, D. D.
    Hamze, J.
    Broadwin, M.
    Stone, C.
    Banerjee, D.
    Sellke, F. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [39] The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
    Spertus, John A.
    Birmingham, Mary C.
    Nassif, Michael
    Damaraju, C., V
    Abbate, Antonio
    Butler, Javed
    Lanfear, David E.
    Lingvay, Ildiko
    Kosiborod, Mikhail N.
    Januzzi, James L.
    NATURE MEDICINE, 2022, 28 (04) : 809 - +
  • [40] The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial
    John A. Spertus
    Mary C. Birmingham
    Michael Nassif
    C. V. Damaraju
    Antonio Abbate
    Javed Butler
    David E. Lanfear
    Ildiko Lingvay
    Mikhail N. Kosiborod
    James L. Januzzi
    Nature Medicine, 2022, 28 : 809 - 813
12345